F.D.A. Rejects Closely Watched Lung Cancer Drug From China
The United States Food and Drug Administration has rejected a closely watched lung cancer drug developed in China, according to recent industry reports.
9 trends tracked about this subject — the full history, oldest to newest below.
The United States Food and Drug Administration has rejected a closely watched lung cancer drug developed in China, according to recent industry reports.
Enveda secures $311 million in venture funding to advance nature-derived AI drugs into clinical trials.
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.